|Articles|September 1, 2003

Melanoma Fighter

Chicago - Arginine deiminase, an amino acid degrading enzyme, is safe and has anti-tumor activity in phase I and II investigations of metastatic melanoma, according to Theodore Logan, M.D.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe

Related Content

Dermatology Times Spot Test: September 6, 2026

ByMarie Bosslett, Assistant Editor

September 6th 2026

Social Media Mythbusters: "Clean" Skin Care

ByMarie Bosslett, Assistant Editor

September 5th 2026

Mind the Gap: Will Digital Replace Clinical?

ByCandice Fortunato, MD

September 4th 2026

Individualizing Sun-Safety Counseling: Matching Patient Goals With Cancer Risk

ByJoshua Arbesman, MD,Marie Bosslett, Assistant Editor

September 4th 2026

AbbVie Completes $10.9 Billion Apogee Acquisition, Adds Zumilokibart to AD Pipeline

ByShannon Heaning, Content Associate

September 3rd 2026

Latest CME

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Melanoma Fighter

Related Content

Dermatology Times Spot Test: September 6, 2026

Social Media Mythbusters: "Clean" Skin Care

Mind the Gap: Will Digital Replace Clinical?

Individualizing Sun-Safety Counseling: Matching Patient Goals With Cancer Risk

AbbVie Completes $10.9 Billion Apogee Acquisition, Adds Zumilokibart to AD Pipeline

Latest CME

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Trending on Dermatology Times

AbbVie Completes $10.9 Billion Apogee Acquisition, Adds Zumilokibart to AD Pipeline

Social Media Mythbusters: "Clean" Skin Care

The Evolving CSU Pipeline: Biologics, BTK Inhibitors, and Biomarker-Guided Care

Journal Digest: September 2, 2026

The Derm Files: Can You Calm This AD Flare?